4.7 Article

Vitamin D and risk of death from vascular and non-vascular causes in the Whitehall study and meta-analyses of 12 000 deaths

期刊

EUROPEAN HEART JOURNAL
卷 34, 期 18, 页码 1365-1374

出版社

OXFORD UNIV PRESS
DOI: 10.1093/eurheartj/ehs426

关键词

Vitamin D; Cardiovascular disease; Mortality

资金

  1. British Heart Foundation
  2. BHF Cardiovascular Research Initiative
  3. Medical Research Council, UK
  4. MRC [MC_U137686857, MC_U137686855] Funding Source: UKRI
  5. Medical Research Council [MC_U137686857, MC_U137686855] Funding Source: researchfish

向作者/读者索取更多资源

To examine the independent relevance of plasma concentrations of 25-hydroxyvitamin D [25(OH)D] for vascular and non-vascular mortality. We examined associations of plasma concentrations of 25(OH)D and cause-specific mortality in a prospective study of older men living in the UK and included findings in meta-analyses of similar studies identified by a systematic search reporting on vascular and all-cause mortality. In a 13-year follow-up of 5409 men (mean baseline age 77 years), 1358 died from vascular and 1857 from non-vascular causes. Median season-adjusted baseline 25(OH)D concentration was 56 (interquartile range: 4567) nmol/L. After adjustment for age and seasonality, higher concentrations of 25(OH)D were inversely and approximately linearly (loglog scale) associated with vascular and non-vascular mortality throughout the range 4090 nmol/L. After additional adjustment for prior disease and cardiovascular risk factors, a doubling in 25(OH)D concentration was associated with 20 [95 confidence interval (CI): 930] lower vascular and 23 (95 CI: 1431) lower non-vascular mortality. In meta-analyses of prospective studies, individuals in the top vs. bottom quarter of 25(OH)D concentrations had 21 (95 CI: 1328) lower vascular and 28 (95 CI: 2432) lower all-cause mortality. Despite strong inverse and apparently independent associations of 25(OH)D with vascular and non-vascular mortality, causality remains uncertain. Large-scale randomized trials, using high doses of vitamin D, are required to assess the clinical relevance of these associations.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Cardiac & Cardiovascular Systems

Pregnancy outcomes in women with a systemic right ventricle and transposition of the great arteries results from the ESC-EORP Registry of Pregnancy and Cardiac disease (ROPAC)

Oktay Tutarel, Lucia Baris, Werner Budts, Mohamad Gamal Abd-El Aziz, Csilla Liptai, David Majdalany, Silvana Jovanova, Alexandra Frogoudaki, Heidi M. Connolly, Mark R. Johnson, Aldo P. Maggioni, Roger Hall, Jolien W. Roos-Hesselink

Summary: The study found that women with an sRV generally tolerated pregnancy well with favorable outcomes for both mother and fetus, with heart failure and arrhythmias being the most common adverse cardiac events. Pre-pregnancy signs of heart failure and sRV ejection fraction <40% were predictors for major adverse cardiac events. There were no significant differences between women with CCTGA and TGA.
Article Medicine, General & Internal

Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Peter W. Horby, Guilherme Pessoa-Amorim, Natalie Staplin, Jonathan R. Emberson, Mark Campbell, Enti Spata, Leon Peto, Nigel J. Brunskill, Simon Tiberi, Victor Chew, Thomas Brown, Hasan Tahir, Beate Ebert, David Chadwick, Tony Whitehouse, Rahuldeb Sarkar, Clive Graham, J. Kenneth Baillie, Buddha Basnyat, Maya H. Buch, Lucy C. Chappell, Jeremy Day, Saul N. Faust, Raph L. Hamers, Thomas Jaki, Edmund Juszczak, Katie Jeffery, Wei Shen Lim, Alan Montgomery, Andrew Mumford, Kathryn Rowan, Guy Thwaites, Marion Mafham, Richard Haynes, Martin J. Landray

Summary: In patients hospitalized with COVID-19, aspirin was not associated with reductions in 28-day mortality or in the risk of progressing to invasive mechanical ventilation or death, but was associated with a small increase in the rate of being discharged alive within 28 days.

LANCET (2022)

Article Medicine, General & Internal

Predictive value of circulating NMR metabolic biomarkers for type 2 diabetes risk in the UK Biobank study

Fiona Bragg, Eirini Trichia, Diego Aguilar-Ramirez, Jelena Besevic, Sarah Lewington, Jonathan Emberson

Summary: This study found that metabolic biomarkers were independently associated with the risk of T2D, and further addition of metabolic biomarker principal components improved the prediction of T2D risk.

BMC MEDICINE (2022)

Article Cardiac & Cardiovascular Systems

Characteristics, management, and outcomes of patients with left-sided infective endocarditis complicated by heart failure: a substudy of the ESC-EORP EURO-ENDO (European infective endocarditis) registry

Yohann Bohbot, Gilbert Habib, Cecile Laroche, Elisabeth Stohr, Catherine Chirouze, Marta Hernandez-Meneses, Maria Melissopoulou, Bulent Mutlu, Valentina Scheggi, Luisa Branco, Carmen Olmos, Graciela Reyes, Michal Pazdernik, Bernard Iung, Rouguiatou Sow, Maja Mirocevic, Patrizio Lancellotti, Christophe Tribouilloy

Summary: The study found that patients with left-sided infective endocarditis complicated by congestive heart failure tend to be older, have more comorbidities, and more severe valve damage, leading to significantly higher 30-day and 1-year mortality rates. Early surgery is strongly associated with lower mortality but is only performed on approximately half of these patients.

EUROPEAN JOURNAL OF HEART FAILURE (2022)

Article Transplantation

Design, recruitment, and baseline characteristics of the EMPA-KIDNEY trial

William G. Herrington, Christoph Wanner, Jennifer B. Green, Sibylle J. Hauske, Parminder Judge, Kaitlin J. Mayne, Sarah Y. A. Ng, Emily Sammons, Doreen Zhu, Natalie Staplin, David Preiss, Will Stevens, Karl Wallendszus, Rejive Dayanandan, Carol Knott, Michael Hill, Jonathan Emberson, Susanne Brenner, Vladimir Cejka, Alfred K. Cheung, Zhihong Liu, Jing Li, Peiling Chen, Laiseong Hooi, Wen Liu, Takashi Kadowaki, Masaomi Nangaku, Adeera Levin, David Cherney, Roberto Pontremoli, Aldo Pietro Maggioni, Shinya Goto, Aiko Tomita, Rajat Deo, Katherine Tuttle, Jens Eilbracht, Stefan Hantel, Mark Hopley, Martin J. Landray, Colin Baigent, Richard Haynes

Summary: The EMPA-KIDNEY trial aims to evaluate the effects of empagliflozin on the risk of kidney disease progression or cardiovascular death in patients with chronic kidney disease. The trial includes a widely generalizable population of CKD patients and uses a streamlined design with minimal data collection. Results are anticipated in 2022.

NEPHROLOGY DIALYSIS TRANSPLANTATION (2022)

Letter Public, Environmental & Occupational Health

Body mass index and COVID-19 mortality: prospective study of 120 000 Mexican adults

Jesus Alegre-Diaz, Louisa G. Friedrichs, Raul Ramirez-Reyes, Rachel Wade, Fiona Bragg, William G. Herrington, Robert Clarke, Richard Peto, Rory Collins, Pablo Kuri-Morales, Jonathan R. Emberson, Roberto Tapia-Conyer

INTERNATIONAL JOURNAL OF EPIDEMIOLOGY (2022)

Article Peripheral Vascular Disease

Determining the Relationship Between Blood Pressure, Kidney Function, and Chronic Kidney Disease: Insights From Genetic Epidemiology

Natalie Staplin, William G. Herrington, Federico Murgia, Maysson Ibrahim, Katherine R. Bull, Parminder K. Judge, Sarah Y. A. Ng, Michael Turner, Doreen Zhu, Jonathan Emberson, Martin J. Landray, Colin Baigent, Richard Haynes, Jemma C. Hopewell

Summary: The study findings provide genetic evidence supporting the causal relationship between blood pressure differences and decreased kidney function, glomerular hyperfiltration, and albuminuria. This conclusion is important for understanding the association between blood pressure and kidney diseases.

HYPERTENSION (2022)

Article Medicine, General & Internal

Angiotensin receptor blockers and β blockers in Marfan syndrome: an individual patient data meta-analysis of randomised trials

Alex Pitcher, Enti Spata, Jonathan Emberson, Kelly Davies, Heather Halls, Lisa Holland, Kate Wilson, Christina Reith, Anne H. Child, Tim Clayton, Matthew Dodd, Marcus Flather, Xu Yu Jin, George Sandor, Maarten Groenink, Barbara Mulder, Julie De Backer, Arturo Evangelista, Alberto Forteza, Gisela Teixido-Tura, Catherine Boileau, Guillaume Jondeau, Olivier Milleron, Ronald Lacro, Lynn A. Sleeper, Hsin-Hui Chiu, Mei-Hwan Wu, Stefan Neubauer, Hugh Watkins, Hal Dietz, Colin Baigent

Summary: In patients with Marfan syndrome, ARBs reduce the rate of increase in the aortic root Z score, including among those taking beta blockers. The effects of beta blockers are similar to those of ARBs. Combination therapy with ARBs and beta blockers provides a more significant reduction in the rate of aortic enlargement than either treatment alone.

LANCET (2022)

Article Cardiac & Cardiovascular Systems

Effects of haemodynamically atrio-ventricular optimized His bundle pacing on heart failure symptoms and exercise capacity: the His Optimized Pacing Evaluated for Heart Failure (HOPE-HF) randomized, double-blind, cross-over trial

Zachary I. Whinnett, Matthew J. Shun-Shin, Mark Tanner, Paul Foley, Badri Chandrasekaran, Philip Moore, Shaumik Adhya, Norman Qureshi, Amal Muthumala, Rebecca Lane, Aldo Rinaldi, Sharad Agarwal, Francisco Leyva, Jonathan Behar, Sukh Bassi, Andre Ng, Paul Scott, Rachana Prasad, Jon Swinburn, Joseph Tomson, Amarjit Sethi, Jaymin Shah, Phang Boon Lim, Andreas Kyriacou, Dewi Thomas, Jenny Chuen, Ravi Kamdar, Prapa Kanagaratnam, Myril Mariveles, Leah Burden, Katherine March, James P. Howard, Ahran Arnold, Pugazhendhi Vijayaraman, Berthold Stegemann, Nicholas Johnson, Emanuela Falaschetti, Darrel P. Francis, John G. F. Cleland, Daniel Keene

Summary: The study evaluated the effects of optimized His bundle pacing compared to no-pacing in patients with heart failure. It was found that His bundle pacing significantly improved quality of life and was preferred by the majority of patients. However, it did not show any significant changes in peak oxygen uptake or left ventricular ejection fraction.

EUROPEAN JOURNAL OF HEART FAILURE (2023)

Article Medicine, General & Internal

Empagliflozin in Patients with Chronic Kidney Disease

William G. Herrington, Natalie Staplin, Christoph Wanner, Jennifer B. Green, Sibylle J. Hauske, Jonathan R. Emberson, David Preiss, Parminder Judge, Kaitlin J. Mayne, Sarah Y. A. Ng, Emily Sammons, Doreen Zhu, Michael Hill, Will Stevens, Karl Wallendszus, Susanne Brenner, Alfred K. Cheung, Zhi-Hong Liu, Jing Li, Lai Seong Hooi, Wen Liu, Takashi Kadowaki, Masaomi Nangaku, Adeera Levin, David Cherney, Aldo P. Maggioni, Roberto Pontremoli, Rajat Deo, Shinya Goto, Xavier Rossello, Katherine R. Tuttle, Dominik Steubl, Michaela Petrini, Dan Massey, Jens Eilbracht, Martina Brueckmann, Martin J. Landray, Colin Baigent, Richard Haynes

Summary: Empagliflozin therapy reduces the risk of disease progression or cardiovascular death in patients with chronic kidney disease.

NEW ENGLAND JOURNAL OF MEDICINE (2023)

Review Cardiac & Cardiovascular Systems

2022 Joint ESC/EACTS review of the 2018 guideline recommendations on the revascularization of left main coronary artery disease in patients at low surgical risk and anatomy suitable for PCI or CABG

Robert A. Byrne, Stephen Fremes, Davide Capodanno, Martin Czerny, Torsten Doenst, Jonathan R. Emberson, Volkmar Falk, Mario Gaudino, John J. Mcmurray, Roxana Mehran, Milan Milojevic, Miguel Sousa Uva

Summary: In October 2021, the ESC and EACTS established a task force to review the 2018 guidelines on myocardial revascularization for patients with LM disease. The task force suggested updated recommendations for revascularization modality, stating that both CABG and PCI are clinically reasonable options for stable patients with LM disease. The task force also acknowledged knowledge gaps and emphasized the need for more data.

EUROPEAN HEART JOURNAL (2023)

Article Cardiac & Cardiovascular Systems

Mechanisms of rosuvastatin-related acute kidney injury following cardiac surgery: the STICS trial

Rohan Wijesurendra, Rebecca Sardell, Raja Jayaram, Nathan Samuel, Zhengming Chen, Natalie Staplin, Rory Collins, Zhe Zheng, Richard Haynes, Michael Hill, Jonathan Emberson, Barbara Casadei

EUROPEAN HEART JOURNAL (2023)

Article Endocrinology & Metabolism

Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Peter W. Horby, Natalie Staplin, Leon Peto, Jonathan R. Emberson, Mark Campbell, Guilherme Pessoa-Amorim, Buddha Basnyat, Louise Thwaites, Rogier van Doorn, Raph L. Hamers, Jeremy Nel, John Amuasi, Manisha Rawal, Dipansu Ghosh, Jonathan Douse, Fergus Hamilton, Anthony Kerry, Pinky Thu-Ta, John Widdrington, Christopher A. Green, Purav Desai, Richard Stewart, Nguyen Thanh Phong, J. Kenneth Baillie, Maya Buch, Saul N. Faust, Thomas Jaki, Edmund Juszczak, Katie Jeffery, Marian Knight, Wei Shen Lim, Alan Montgomery, Aparna Mukherjee, Andrew Mumford, Kathryn Rowan, Guy Thwaites, Marion Mafham, Richard Haynes, Martin J. Landray

Summary: Empagliflozin is not associated with reduced mortality, hospital stay, or progression to invasive mechanical ventilation or death in hospitalized adults with COVID-19.

LANCET DIABETES & ENDOCRINOLOGY (2023)

Article Public, Environmental & Occupational Health

Educational and social inequalities and cause-specific mortality in Mexico City: a prospective study

Thomas Addey, Jesus Alegre-Diaz, Fiona Bragg, Eirini Trichia, Rachel Wade, Rogelio Santacruz-Benitez, Raul Ramirez-Reyes, Adrian Garcilazo-Avila, Carlos Gonzales-Carballo, Omar Yaxmehen Bello-Chavolla, Neftali Eduardo Antonio-Villa, Diego Aguilar-Ramirez, Louisa Gnatiuc Friedrichs, Sarah Lewington, Richard Peto, Rory Collins, Jaime Berumen, Jonathan R. Emberson, Pablo Kuri-Morales, Roberto Tapia-Conyer

Summary: There are marked educational inequalities in premature adult mortality in this Mexican population, which are largely accounted for by lifestyle and related risk factors. Effective interventions targeting these risk factors could reduce inequalities and have a significant impact on premature mortality.

LANCET PUBLIC HEALTH (2023)

Article Medicine, General & Internal

Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Peter W. Horby, Marion Mafham, Leon Peto, Mark Campbell, Guilherme Pessoa-Amorim, Enti Spata, Natalie Staplin, Jonathan R. Emberson, Benjamin Prudon, Paul Hine, Thomas Brown, Christopher A. Green, Rahuldeb Sarkar, Purav Desai, Bryan Yates, Tom Bewick, Simon Tiberi, Tim Felton, J. Kenneth Baillie, Maya H. Bitch, Lucy C. Chappell, Saul N. Faust, Thomas Jaki, Katie Jeffery, Edmund Juszczak, Wei Shen Lim, Alan Montgomery, Andrew Mumford, Kathryn Rowan, David M. Weinreich, Richard Haynes, Martin J. Landray

Summary: This study evaluated the efficacy and safety of the combination therapy of casirivimab and imdevimab in patients hospitalized with COVID-19. The results showed that this combination therapy reduced the 28-day mortality rate in patients without detectable antibodies to SARS-CoV-2 infection at baseline, but not in those with detectable antibodies.

LANCET (2022)

暂无数据